A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma.

导出 LinkOut

翻译打印收藏纠错

第一作者： Matthew J,Cortese

第一单位： Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland, OH, USA.

作者： Matthew J,Cortese ^[1] ; Wei,Wei ^[2] ; Sebastian,Cerdeña ^[3] ; Marcus P,Watkins ^[3] ; Marissa,Olson ^[3] ; Gray,Jodon ^[4] ; Jeff,Kaiser ^[4] ; Bradley,Haverkos ^[4] ; Mitchell E,Hughes ^[5] ; Esin,Namoglu ^[5] ; Natalie S,Grover ^[6] ; Anson,Snow ^[6] ; Victor,Orellana-Noia ^[7] ; Magdalena,Rainey ^[8] ; Mohammad,Sohail ^[8] ; Joslyn,Rudoni ^[9] ; Craig,Portell ^[7] ; Timothy,Voorhees ^[6] ; Daniel J,Landsburg ^[5] ; Manali,Kamdar ^[4] ; Brad S,Kahl ^[3] ; Brian T,Hill ^[1]

作者单位： Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland, OH, USA. ^[1] Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Lerner Research Institute, Cleveland, OH, USA. ^[2] Barnes-Jewish Hospital, Washington University in St. Louis, St. Louis, MO, USA. ^[3] University of Colorado Cancer Center, Aurora, CO, USA. ^[4] Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. ^[5] Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. ^[6] Division of Hematology/Oncology, University of Virginia, Charlottesville, VA, USA. ^[7] Lerner College of Medicine, Cleveland Clinic, Cleveland, OH, USA. ^[8] Department of Pharmacy, Cleveland Clinic, Cleveland, OH, USA. ^[9]

关键词 DA-EPOCH-R Double/triple-hit lymphomas chemoimmunotherapy chemotherapy high-grade B-cell lymphomas lymphoma